New Directions in the Treatment of Non-Muscle Invasive Bladder Cancer : Episode 3

Opinion

Video

February 4, 2025

Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

Experts discuss the evolving landscape of chemotherapy and immunotherapy options for patients with non-muscle invasive bladder cancer (NMIBC).

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.A Comprehensive Overview of NMIBC

EP: 2.Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP: 3.Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP: 4.New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP: 5.Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP: 6.Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP: 7.The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP: 8.Navigating The Future of NMIBC Trails: Key Insights and Takeaways

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos

Ongoing Investigations: Expanding the Role of Cretostimogene in NMIBC Care

Ongoing Investigations: Expanding the Role of Cretostimogene in NMIBC Care

Diving Deeper: Discussing Results From Cohort C in the BOND-003 Trial

Diving Deeper: Discussing Results From Cohort C in the BOND-003 Trial

2 experts are featured in this series.

Overcoming Challenges for Wider Adoption of TLX250

1 expert is featured in this series.

The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions

1 expert is featured in this series.

Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability

2 experts are featured in this series.

Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial

Topline Data From the BOND-003 Trial in NMIBC

Topline Data From the BOND-003 Trial in NMIBC

1 expert is featured in this series.

Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection

1 expert is featured in this series.

A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Related Content

Related Content

Peer Exchange New Directions in the Treatment of Non-Muscle Invasive Bladder Cancer

|

New Directions in the Treatment of Non-Muscle Invasive Bladder Cancer

Recent Content

Use of surgical therapy for erectile dysfunction remains low, study shows

Use of surgical therapy for erectile dysfunction remains low, study shows

Conceptual image for viral ethiology of prostate cancer. 3D illustration showing Human Papilloma Viruses HPV infecting prostate gland which develops cancerous tumor | Image Credit: © Dr_Microbe - stock.adobe.com

Biden’s prostate cancer diagnosis underscores importance of screening, awareness

Colorful DNA molecule. Concept image of a structure of the genetic code. | Image Credit: © ktsdesign - stock.adobe.com

Genomic test can predict resistance to chemotherapy in prostate cancer

3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

177Lu-rhPSMA-10.1 injection shows positive radiation dosimetry results in mCRPC

View More Recent Content

Terms and Conditions

Do not sell my Personnal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.